Form 4: Edwards Lifesciences CVP Reports Tax-Related Share Sale

Edwards Lifesciences CVP Daniel J. Lippis reported the disposition of 432 common shares at $79.78 each for tax withholding purposes.

Summary

• Daniel J. Lippis, Corporate Vice President of TAVR at Edwards Lifesciences Corp (EW), reported a transaction on February 22, 2026.
• The transaction involved the disposition of 432 shares of Edwards Lifesciences common stock.
• The shares were disposed of at a price of $79.78 per share.
• Following this transaction, Mr. Lippis beneficially owns 33,933.9103 shares of the company's common stock.
• The transaction code 'F' indicates that these shares were disposed of to cover tax withholding obligations related to equity awards.

Sentiment

Score: 5

Explanation: StockSavvy.ai views this as a neutral event, typical for executive compensation and tax planning, with no direct positive or negative implications for the company's operational performance or future prospects.

Positives

• The transaction is a disposition of shares for tax withholding, not a discretionary sale by management, which is a routine part of executive compensation.

Negatives

• No direct negative implications as the transaction is for tax withholding purposes, not a discretionary sale indicating a lack of confidence.

Future Outlook

This filing, a Form 4, does not contain any forward-looking statements or guidance regarding the company's future outlook.

Industry Context

StockSavvy.ai notes that routine insider transactions, such as dispositions for tax withholding, are common occurrences across publicly traded companies and generally do not signal significant changes in company outlook or insider sentiment. This transaction is specific to an individual executive's equity compensation and tax planning.

Comparison to Industry Standards

• This is a standard Form 4 filing reporting an insider transaction related to equity compensation. Such tax-related dispositions are common across publicly traded companies when equity awards vest or options are exercised. For example, executives at medical device companies like Medtronic (MDT) or Boston Scientific (BSX) frequently report similar tax-related share dispositions as part of their compensation plans.

Stakeholder Impact

• Shareholders: Minimal direct impact as this is a routine tax-related disposition, not a discretionary sale indicating a change in management's confidence in the company.
• Employees: No direct impact on the broader employee base.

Key Dates

Recommendation

This Form 4 reports a routine disposition of shares for tax withholding purposes by an executive, which is a common occurrence related to equity compensation. It does not reflect a discretionary sale based on new information or a change in the company's fundamental outlook, thus warranting no change to an existing 'hold' recommendation.

Keywords

Edwards Lifesciences, EW, Insider Transaction, Form 4, Daniel J. Lippis, Tax Withholding, Beneficial Ownership